2nd World Immunotherapy Council Young Investigator Symposium Schedule

Wednesday, Nov. 8

1 1:05 p.m. Welcome & Introductions
Tanja de Gruijl, PhD VU University Medical Center
Graham Pawelec, PhD – University of Tuebingen

Session I: Checkpoint Blockade

Senior Co-Chairs:

Beatrix Kotlan, PhD National Institute of Oncology, Budapest
Sacha Gnjatic, PhD Cancer Research Institute (CRI)
Zihai Li, MD, PhD – Chinese American Hematology Oncology Network (CAHON)
Lisa H. Butterfield Society of Immunotherapy of Cancer (SITC)

1:05  1:10 p.m. Welcome & Introductions
Junior Co-Chair: Hong Zheng, MD, PhD Pennsylvania State Cancer Institute
1:10 1:25 p.m. Immunotherapy - Long Term Survival Metastic Melanoma
Katalin Czirbesz, MD National Institute of Oncology, Budapest
1:25 1:40 p.m. PD-1 Blockade: Understanding CD8 T Cell Rescue for Insights into Cancer Immunotherapy
Alice O. Kamphorst, PhD Cancer Research Institute (CRI)
1:40 1:55 p.m. Oncolytic Viral Immunotherapy in the Era of Immune Checkpoint Blockade
Liang Deng, MD, PhD Chinese American Hematology Oncology Network
1:55 2:10 p.m. Treg Modulation as a Pharmacodynamic Biomarker of GITR Stimulation in Cancer Patients
Roberta Zappasodi, PhD Society for Immunotherapy of Cancer
2:10 2:20 p.m. Break

Session II: Adoptive T Cell Therapy

Senior Co-Chairs:

Robert E. Hawkins, MD, PhD Adaptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK)
Willemijn Hobo, PhD Dutch Tumor Immunology Working Party (DTIWP)
Per Thor Straten, PhD Progress in Vaccination Against Cancer (PIVAC)
2:20 2:25 p.m. Welcome & Introductions
Junior Co-Chair: Marco Ruella, MD – University of Pennsylvania
2:25 2:40 p.m. Exploiting Tumor Infiltrating Lymphocytes (Tils) as a Therapeutic Strategy for Epithelial Ovarian Cancer
Gemma Owens, BSc, MB, BCh, MRes Adoptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK)
2:40 2:55 p.m. TBD
2:55 3:10 p.m. Combined Killing of Cancer Cells and Cross Presentation of Tumor Antigens by Vγ9Vδ2 T Cells
Gitte Holmen Olofsson Progress in Vaccination Against Cancer (PIVAC)
3:10 3:25 p.m. TBD
3:25 3:35 p.m. Break

Session III: Innate Immunity

Senior Co-Chairs:

Weihua Xiao, MD, MS Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio-Therapy (TIBT)
Heinz Zwierzina, MD – Cancer Drug Development Forum (Biotherapy Development Association)
Angus Dalgleish, MD, PhD – Institute for Cancer Vaccines and Immunotherapy (ICVI)


3:35 3:40 p.m. Welcome & Introductions
Junior Co-Chair: Cheng Sun, MD, PhD Chinese Academy of Sciences and University of Science and Technology of China
3:40 3:55 p.m. Dysfunction of Dendritic Cells in Lung Cancer
Fang Fang, PhD – Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio-Therapy (TIBT)
3:55 4:10 p.m. Development of a Novel Immunotherapy with Toll-Like and Nod-Like Receptors Synergy for Targeted Cancer Therapy
Celia Jacoberger-Foissac Cancer Drug Development Forum (Biotherapy Development Association)
4:10 4:25 p.m. Zoledronic Acid Induces Gamma Delta T Cells to Target MacrophagesDaniel William Fowler, PhD Institute for Cancer Vaccines and Immunotherapy (ICVI)
4:25 4:40 p.m. TBD
4:40 5:40 p.m. Break

Session IV: Novel Approaches to Improve Immunotherapy

Senior Co-Chairs:

Kazuhiro Kakimi, MD, PhD Japanese Association of Cancer Immunotherapy (JACI)
Barbara Seliger, MD, PhD Tumor Immunology Meets Oncology (TIMO)
Michele Maio, MD, PhD NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori)
Giuseppe Masucci, MD, PhD Scandinavian Network for Immunotherapy of Cancer
5:40 5:45 p.m. Welcome & Introductions
Junior Co-Chair: Margot Pont, PhD Fred Hutchinson Cancer Research Center
5:45 6 p.m. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Cancer Immunotherapy
Takahiro Karasaki, MD Japanese Association of Cancer Immunology (JACI)
6 6:15 p.m.

Reversing the Tumor Immune Escape with Selenium
Claudia Lennicke, PhD – Tumor Immunology Meets Oncology (TIMO)

6:15 6:30 p.m.

Epigenetic Immunomodelling to Improve the Efficacy of Cancer
Immunotherapy
Alessia Covre, PhD – NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori)

6:30 6:45 p.m.

Blood in Circulation, with Intact Cascade Systems, as a Tool to Predict First-
Infusion Reactions and Mechanism of- Action of Immunotherapeutics
Erika Fletcher, MSc – Scandinavian Network for Immunotherapy of Cancer

6:45 7 p.m.

Closing Remarks
Graham Pawelec, PhD
University of Tuebingen